Next Article in Journal / Special Issue
Statin Pharmacogenomics: Opportunities to Improve Patient Outcomes and Healthcare Costs with Genetic Testing
Previous Article in Journal / Special Issue
A Database-driven Decision Support System: Customized Mortality Prediction
Article Menu

Export Article

Open AccessCase Report
J. Pers. Med. 2012, 2(4), 149-157; doi:10.3390/jpm2040149

Cases of Adverse Reaction to Psychotropic Drugs and Possible Association with Pharmacogenetics

University of Western Sydney Clinic and Research Centre Blacktown, Western Sydney Local Health District, Blacktown 2148, NSW, Australia
*
Author to whom correspondence should be addressed.
Received: 24 August 2012 / Revised: 21 September 2012 / Accepted: 21 September 2012 / Published: 1 October 2012
View Full-Text   |   Download PDF [275 KB, uploaded 1 October 2012]

Abstract

Thousands of samples for pharmacogenetic tests have been analysed in our laboratory since its establishment. In this article we describe some of the most interesting cases of CYP poor metabolisers associated with adverse reactions to psychotropic drugs. Prevention of disease/illness, including Adverse Drug Reaction (ADR), is an aim of modern medicine. Scientific data supports the fact that evaluation of drug toxicology includes several factors, one of which is genetic variations in pharmacodynamics and pharmacokinetics of drug pathways. These variations are only a part of toxicity evaluation, however, even if it would help to prevent only a small percentage of patients from suffering adverse drug reactions, especially life threatening ADRs, pharmacogenetic testing should play a significant role in any modern psychopharmacologic practice. Medical practitioners should also consider the use of other medications or alternative dosing strategies for drugs in patients identified as altered metabolisers. This will promise not only better and safer treatments for patients, but also potentially lowering overall healthcare costs.
Keywords: venlafaxine; nortriptyline; suicide; adverse effects; genetic polymorphisms; cytochrome P450; pharmacogenetics venlafaxine; nortriptyline; suicide; adverse effects; genetic polymorphisms; cytochrome P450; pharmacogenetics
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Supplementary material

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Piatkov, I.; Jones, T.; McLean, M. Cases of Adverse Reaction to Psychotropic Drugs and Possible Association with Pharmacogenetics. J. Pers. Med. 2012, 2, 149-157.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Pers. Med. EISSN 2075-4426 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top